WO2015108394A1 - 히드록시 피라논 유도체 화합물을 포함하는 지방세포 분화 촉진용 화장료 조성물 - Google Patents
히드록시 피라논 유도체 화합물을 포함하는 지방세포 분화 촉진용 화장료 조성물 Download PDFInfo
- Publication number
- WO2015108394A1 WO2015108394A1 PCT/KR2015/000560 KR2015000560W WO2015108394A1 WO 2015108394 A1 WO2015108394 A1 WO 2015108394A1 KR 2015000560 W KR2015000560 W KR 2015000560W WO 2015108394 A1 WO2015108394 A1 WO 2015108394A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- present
- skin
- adipocytes
- volume
- Prior art date
Links
- 0 *Oc1cc(C=CC(OCC(OC=C2O)=CC2=O)=O)ccc1O Chemical compound *Oc1cc(C=CC(OCC(OC=C2O)=CC2=O)=O)ccc1O 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- the present specification relates to a cosmetic composition for promoting adipocyte differentiation.
- adipose tissue which plays a role in determining the volume and strength of the skin. Therefore, as mentioned above, increasing the volume of adipose tissue may be a good solution to maintain the volume and elasticity of the skin rather than the method of imparting elasticity to the dermis or epidermis in the outer skin layer.
- adipocytes commonly used adipocytes (preadipocytes) are widely used cells because they have the property of differentiating into adipocytes by differentiation inducing substances such as insulin. Recently, the mesenchymal stem cell (mesenchymal stem cell) is attracting attention in the study using such fat cells.
- Adipose-derived mesenchymal stem cells can be differentiated using methods similar to those used to differentiate adipocytes into adipocytes (Exp. Cell Res. 2006, 312, 1856-1864). It is widely used (Science 1999, 284, 143-146). These adipose-derived mesenchymal stem cells are known to be differentiated into not only fat cells but also other types of cells such as chondrocytes and bone cells (J. Cell Sci. 2006 119, 2204-2213). It is distributed.
- the present inventors have completed the present invention by confirming that a compound having a specific structure exhibits a fat cell differentiation promoting effect among the hydroxy pyranone derivatives while studying a compound having a fat cell differentiation promoting effect.
- compositions for promoting adipocyte differentiation, skin volume or elasticity enhancement comprising such a hydroxy pyranone derivative compound.
- the present disclosure provides a composition for promoting adipocyte differentiation, skin volume or elasticity enhancement comprising a hydroxy pyranone derivative as an active ingredient.
- the composition according to the present disclosure includes an hydroxy pyranone derivative as an active ingredient, and exhibits an effect of promoting differentiation of adipocytes, thereby enhancing the volume or elasticity of the skin. More specifically, it can promote the differentiation of human mesenchymal stem cells into adipocytes, thereby producing a lipid droplet, which can have an effect of enhancing the volume and elasticity of the skin. Therefore, the composition of the present disclosure may be variously used in the cosmetic or pharmaceutical field.
- FIG. 1 is a microscope photograph showing the results of experiments inducing adipocyte differentiation of a hydroxy pyranone derivative compound according to an aspect of the present invention.
- Korean Patent Application No. 10-2014-0006640 filed January 20, 2014, is incorporated herein by reference in its entirety for all purposes. This application also claims the benefit of Korean Patent Application No. 10-2014-0006640, which is hereby incorporated by reference in its entirety.
- the present invention relates to a composition for enhancing skin volume or elasticity, comprising a hydroxy pyranone derivative compound represented by Formula 1 as an active ingredient.
- R is -CH 2- , or -CH 2 CH 2- .
- the present invention provides a method for enhancing skin volume or elasticity, comprising administering a hydroxy pyranone derivative compound represented by Chemical Formula 1, or a composition comprising the same as an active ingredient, to an individual in need of enhancing skin volume or elasticity. It may be about.
- the administration in the above method may be carried out according to the administration method and administration dose described herein.
- the present invention may be directed to a hydroxy pyranone derivative compound represented by Chemical Formula 1, or a composition comprising the same as an active ingredient, for use in enhancing skin volume or elasticity.
- the present invention may be directed to a skin volume or elasticity enhancing use of the hydroxy pyranone derivative compound represented by Chemical Formula 1.
- the present invention may relate to the use of a hydroxy pyranone derivative compound represented by Chemical Formula 1 in the preparation of a composition for enhancing skin volume or elasticity.
- the composition according to one aspect of the invention may be to promote the differentiation of mesenchymal stem cells (mesenchymal stem cells) into adipocytes.
- the mesenchymal stem cells may be human mesenchymal stem cells.
- the composition according to an aspect of the present invention may have a concentration of the active ingredient of 0.01 ⁇ M to 100 ⁇ M based on the total volume of the composition.
- the concentration of the active ingredient is 0.001 ⁇ M or more, 0.01 ⁇ M or more, 0.1 ⁇ M or more, 0.5 ⁇ M or more, 1 ⁇ M or more, 5 ⁇ M or more, 10 ⁇ M or more, 20 ⁇ M or more, 25 ⁇ M or more based on the total volume of the composition , At least 28 ⁇ M, at least 29 ⁇ M, at least 30 ⁇ M, at least 31 ⁇ M, at least 32 ⁇ M, at least 35 ⁇ M, at least 40 ⁇ M, at least 50 ⁇ M, at least 100 ⁇ M, at least 200 ⁇ M, at least 500 ⁇ M, at least 1mM, at least 10mM, at least 50mM, at least 100mM, at least 1M, or It may be more than 5M and may be less than 10M.
- the concentration of the active ingredient is 0.001 ⁇ M or more, 0.01 ⁇ M or more, 0.1 ⁇
- composition according to one aspect of the invention may be characterized by increasing adipose tissue.
- composition according to one aspect of the invention may be characterized by increasing the skin volume.
- composition according to one aspect of the invention may be characterized in that to increase the skin elasticity.
- the composition according to one aspect of the invention may be a pharmaceutical, food or cosmetic composition.
- the present invention in one aspect, as a method for producing a hydroxy pyranone derivative represented by the formula (1),
- R is -CH 2- , or -CH 2 CH 2- .
- hydroxy pyranone derivative compound of the formula (1) obtained by the manufacturing method according to one aspect of the present invention (2E)-(5-hydroxy-4-oxo-4H-pyran-2-yl) methyl 3 -(Benzo [d] [1,3] dioxo-6-yl) acrylate, and (2E)-(5-hydroxy-4-oxo-4H-pyran-2-yl) methyl 3- (2, 3-dihydroxybenzo [b] [1,4] dioxo-7-yl) acrylate is mentioned.
- the present invention in one aspect, may be directed to a composition for enhancing skin volume or elasticity comprising a hydroxy pyranone derivative compound prepared by the manufacturing method according to an aspect of the present invention as an active ingredient.
- the hydroxy pyranone derivative compound represented by Formula 1 prepared by the manufacturing method according to an aspect of the present invention may generate and accumulate fat globules by promoting adipocyte differentiation, thereby improving skin elasticity and increasing skin volume. It can be promoted.
- the present invention in one aspect, as a composition for promoting adipocyte differentiation
- composition for promoting adipocyte differentiation comprising a hydroxy pyranone derivative compound represented by the following Chemical Formula 1 as an active ingredient.
- R is -CH 2- , or -CH 2 CH 2- .
- the present invention relates to a method for promoting adipocyte differentiation comprising administering a hydroxy pyranone derivative compound represented by Formula 1 or a composition comprising the same as an active ingredient to an individual in need of promoting adipocyte differentiation.
- a method for promoting adipocyte differentiation comprising administering a hydroxy pyranone derivative compound represented by Formula 1 or a composition comprising the same as an active ingredient to an individual in need of promoting adipocyte differentiation.
- the administration in the above method may be carried out according to the administration method and administration dose described herein.
- the present invention may relate to a hydroxy pyranone derivative compound represented by Chemical Formula 1 for use in promoting adipocyte differentiation or a composition comprising the same as an active ingredient.
- the present invention may be directed to the use of hydroxy pyranone derivative compounds represented by Formula 1 to promote adipocyte differentiation.
- the present invention may relate to the use of a hydroxy pyranone derivative compound represented by Chemical Formula 1 in the preparation of a composition for promoting adipocyte differentiation.
- skin refers to an organ that covers the exterior of an organism and is composed of the epidermis, dermis and subcutaneous fat layer and includes the scalp and hair as well as tissues covering the outside of the face or the entire body. to be.
- volume may refer to a volume, volume, or volume of the skin layer surface or inside, and may refer to a sense of volume exposed to the outer surface.
- volume may refer to a volume, volume, or volume of the skin layer surface or inside, and may refer to a sense of volume exposed to the outer surface.
- the appearance will look firm, healthy and youthful.
- the skin is damaged due to an external force, a wound, a burn, or a burn, the resulting scar, a dent in the outer surface of the skin, or an incision in the skin or tissue due to surgery, etc.
- the volume is increased, the volume of the tissue and the skin layer of the damaged part may be increased, and the skin or tissue may be repaired to have an effect of approaching the original state.
- volume enhancement means that the volume of the skin layer is increased and increased, or that the appearance of the outer surface of the skin means that the volume is enhanced and taut, which is healthy, or that the damaged skin tissue is repaired to get closer to its original state. Can mean. Therefore, when the volume of the skin tissue is increased, the volume of the portion of the skin layer is increased and the surface of the skin is stretched together, thereby increasing the volume of the damaged skin tissue, thereby increasing the volume of the skin layer and bringing the skin closer to its original state. Can be represented.
- the cosmetic composition according to an aspect of the present invention is not particularly limited in formulation, and may be appropriately selected as desired.
- skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing It may be prepared in any one or more formulations selected from the group consisting of foam, cleansing lotion, cleansing cream, body lotion and body cleanser, but is not limited thereto.
- the carrier component is animal fiber, vegetable fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc Or zinc oxide may be used.
- the formulation of the cosmetic composition according to an aspect of the present invention is a powder or a spray
- lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as the carrier component, and particularly in the case of a spray Propellants such as chlorofluorohydrocarbons, propane / butane or dimethyl ether.
- a solvent, a solvating agent or an emulsifying agent is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl Fatty acid esters of benzoate, propylene glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
- a liquid diluent such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester may be used as a carrier component.
- a suspending agent microcrystalline cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
- an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarco Cinates, fatty acid amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
- the cosmetic composition according to an aspect of the present invention may further include a functional additive and a component included in a general cosmetic composition in addition to the hydroxy pyranone derivative compound.
- the functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extract.
- a component contained in a general cosmetic composition may be blended with the functional additive as necessary.
- oils and fats moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, blood circulation And accelerators, cooling agents, limiting agents, purified water, and the like.
- one aspect of the present invention relates to an external preparation for skin comprising a hydroxy pyranone derivative compound as an active ingredient
- the external preparation for skin is a generic term that may include anything applied outside the skin, and cosmetics of various formulations are included herein. Can be included.
- the pharmaceutical composition according to one aspect of the present invention may be various oral or parenteral formulations.
- diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
- Solid form preparations for oral administration include tablets, pills, powders, granules, soft or hard capsules, and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, or the like. Or lactose, gelatin, or the like is mixed.
- lubricants such as magnesium stearate, talc and the like are also used.
- Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
- non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used.
- As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
- compositions according to one aspect of the invention may be used in the form of their pharmaceutically acceptable salts, and may also be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection.
- the salt is not particularly limited as long as it is pharmaceutically acceptable.
- hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid , Benzene sulfonic acid, toluene sulfonic acid, naphthalene sulfonic acid and the like can be used.
- composition according to one aspect of the present invention may be parenterally or orally administered as desired, and may be administered once to several times so as to be administered in an amount of 0.1 to 500 mg, preferably 1 to 100 mg per kg of body weight per day. It can be administered separately. Dosage for a particular patient may vary depending on the patient's weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion, severity of disease, and the like.
- the pharmaceutical composition according to one aspect of the present invention may be a powder, granules, tablets, soft or hard capsules, suspensions, emulsions, syrups, aerosols, oral formulations, ointments, creams, etc. It may be used in any form suitable for pharmaceutical preparations, including suppositories, injectables and sterile injectable solutions, and preferably in the form of injections or external preparations for the skin.
- composition according to an aspect of the present invention may be administered to mammals such as rats, mice, livestock, humans by various routes, such as parenteral, oral, and all modes of administration may be expected. It can be administered orally, rectally or by intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
- composition according to one aspect of the present invention may be administered by various routes that can be easily applied by those skilled in the art.
- the pharmaceutical composition according to an aspect of the present invention may be administered by a route applied to the skin surface as an external preparation for skin.
- the food composition may be a nutraceutical composition.
- the formulation of the food composition according to one aspect of the present invention is not particularly limited, but may be, for example, formulated into a liquid such as tablets, granules, powders, drinks, caramels, gels, bars, and the like.
- the food composition of each formulation may be suitably selected by a person skilled in the art according to the formulation or purpose of use in addition to the active ingredient, and may be synergistic when applied simultaneously with other raw materials.
- the dosage determination of the active ingredient is within the level of those skilled in the art, the daily dosage of which is for example 0.1 mg / kg / day to 5000 mg / kg / day, more specifically The amount may be 50 mg / kg / day to 500 mg / kg / day, but is not limited thereto and may vary depending on various factors such as age, health condition, and complications of the subject to be administered.
- Food composition for example, chewing gum, caramel products, candy, ice cream, confectionery, such as various food products, soft drinks, mineral water, alcoholic beverages, such as beverage products, vitamins and minerals Functional foods.
- the food composition according to an aspect of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors such as flavoring agents, colorants and enhancers (such as cheese, chocolate), pectic acid and salts thereof , Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
- functional food compositions according to an aspect of the present invention may include a pulp for the production of natural fruit juice and fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not so critical but is typically included in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition according to one aspect of the invention.
- a target product (5.0 g, 57%) was obtained as an off-white solid in the same manner as in Example 1, except that 3,4-ethylene dioxy cinnamic acid was used instead of 3,4-methylene dioxy cinnamic acid.
- hAT-MSCs Human adipose tissue derived mesenchymal stem cells
- hAT-MSCs Human adipose tissue derived mesenchymal stem cells
- differentiation of mesenchymal stem cells into adipocytes was obtained by incubating 1 g / ml of insulin, 1 M of dexamethasone (DEXA), 0.5 mM of isobutylmethylxanthine (IBMX) and TRO 2M in the culture of mesenchymal stem cells.
- I was.
- 30 ⁇ M concentration of the compound of Example 1 was added to the medium at the induction of adipocyte differentiation.
- 30 ⁇ M of glibenclamide was used and treated with IDX medium.
- Adiponectin is a representative protein hormone secreted by adipocytes. Such adiponectin has been reported to increase its expression as adipocytes differentiate. Therefore, the amount of adiponectin released as an indicator of adipocyte differentiation was measured in the cell culture medium.
- the medium was harvested from adipocyte-derived mesenchymal stem cells purchased from Lonza Corp. on the 14th day of differentiation into adipocytes, followed by adiponectin ELISA kit (R & D systems, cat. No. DY1065) was used to quantify the amount of adiponectin (each data value was corrected with the control).
- Specific measurement method using adiponectin ELISA kit is as follows.
- the capture antibody was reacted in a 96-well plate, washed with a washing buffer, and the sample was treated at 60 ⁇ M for 2 hours at room temperature. Thereafter, wash three times as each step passes, adding detection antibody, HRP enzyme, substrate solution, stop solution, and reacting for the time indicated in the protocol. . After the final reaction, the absorbance is measured at a wavelength of 450 nm using a spectrophotometer. The results are shown in Table 1 below.
- Example 1 and Example 2 compounds are kojic acid ester compounds. According to Table 1, koji acid did not show an effect in the increase of adiponectin expression, but Example 1 and Example 2 compound increased the amount of adiponectin expression. In the case of the embodiments according to the present invention, it can be seen that the positive control group, cbenclamide, and its expression amount are not significantly different. Therefore, a hydroxy pyranone derivative compound or a composition comprising the same according to an aspect of the present invention is markedly fat. It was confirmed that there is an effect of promoting cell differentiation, and accordingly, it showed an effect that can promote skin volume or elasticity.
- hydroxy pyranone derivatives of Example 1 or 2 vitamin E 9 mg, vitamin C 9 mg, palm oil 2 mg, vegetable hardened oil 8 mg, beeswax 4 mg and lecithin 9 mg were mixed and mixed according to a conventional method to prepare a soft capsule filler.
- 400 mg per capsule is filled to prepare a soft capsule.
- a soft capsule sheet was prepared at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerine, and 10 parts by weight of sorbitol solution and filled with the filler to prepare a soft capsule containing 400 mg of the composition according to an aspect of the present invention. do.
- Injectables were prepared by conventional methods according to the compositions set forth in Table 2 below.
- composition ratio of the said vitamin and mineral mixture was mixed and consisted with the component suitable for a health functional food in a preferable Example, you may change arbitrarily the compounding ratio.
- Table 4 Compounding ingredient content Hydroxy pyranone derivative of Example 1 or 2 1000 mg Citric acid 1000 mg oligosaccharide 100 g Taurine 1 g Purified water Remaining amount
- the above ingredients are mixed according to a conventional method for preparing a health beverage, then stirred and heated at 85 ° C. for about 1 hour, and then the resulting solution is filtered and sterilized.
- composition shown in Table 5 was prepared in the conventional method for the flexible cosmetic.
- Nutritional longevity was prepared according to the composition described in Table 6 below in a conventional manner.
- Nutritional cream was prepared in a conventional manner according to the composition shown in Table 7.
- Table 8 Compounding ingredient Content (% by weight) Hydroxy pyranone derivative of Example 1 or 2 2.0 glycerin 8.0 Butylene glycol 4.0 Liquid paraffin 45.0 Beta Glucan 7.0 Carbomer 0.1 Caprylic / Capric Triglycerides 3.0 Beeswax 4.0 Cetearyl Glucoside 1.5 Sesqui oleic acid sorbitan 0.9 Vaseline 3.0 paraffin 1.5 Preservative, coloring, flavoring Quantity Purified water Remaining amount
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
물질 | 아디포넥틴 (pg/ml, Avg ± S.D.) |
비처리군 | 32 ± 11 |
IDX 처리군 | 302 ± 50 |
IDX + 글리벤클라마이드 | 1832 ± 110 |
IDX + 코지산(kojic acid) (60 μM) | 312 ± 103 |
IDX + 실시예 1 (60 μM) | 1435 ± 113 |
IDX + 실시예 2 (60 μM) | 1300 ± 140 |
배합 성분 | 함량 |
실시예 1 또는 2의 히드록시 피라논 유도체 | 10-50 mg |
주사용 멸균 증류수 | 적량 |
pH 조절제 | 적량 |
배합 성분 | 함량 |
실시예 1 또는 2의 히드록시 피라논 유도체 | 20mg |
비타민 A 아세테이트 | 70μg |
비타민 E | 1.0mg |
비타민 B1 | 0.13mg |
비타민 B2 | 0.15mg |
비타민 B6 | 0.5mg |
비타민 B12 | 0.2μg |
비타민 C | 10mg |
비오틴 | 10μg |
니코틴산아미드 | 1.7mg |
엽산 | 50μg |
판토텐산 칼슘 | 0.5mg |
황산 제1철 | 1.75mg |
산화아연 | 0.82mg |
탄산마그네슘 | 25.3mg |
제1인산칼륨 | 15mg |
제2인산칼슘 | 55mg |
구연산칼륨 | 90mg |
탄산칼슘 | 100mg |
염화마그네슘 | 24.8mg |
배합 성분 | 함량 |
실시예 1 또는 2의 히드록시 피라논 유도체 | 1000mg |
구연산 | 1000mg |
올리고당 | 100 g |
타우린 | 1g |
정제수 | 잔량 |
배합 성분 | 함량 (중량 %) |
실시예 1 또는 2의 히드록시 피라논 유도체 | 0.2 |
글리세린 | 3.0 |
부틸렌글리콜 | 2.0 |
프로필렌글리콜 | 2.0 |
카르복시비닐폴리머 | 0.1 |
피이지-12 노닐페닐에테르 | 0.2 |
폴리솔베이트 80 | 0.4 |
에탄올 | 10.0 |
트리에탄올아민 | 0.1 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
배합 성분 | 함량 (중량 %) |
실시예 1 또는 2의 히드록시 피라논 유도체 | 1.0 |
글리세린 | 3.0 |
부틸렌글리콜 | 3.0 |
프로필렌글리콜 | 3.0 |
카르복시비닐폴리머 | 0.1 |
밀납 | 4.0 |
폴리솔베이트 60 | 1.5 |
카프릴릭/카프릭 트리글리세라이드 | 5.0 |
스쿠알란 | 5.0 |
솔비타세스퀴올레이트 | 1.5 |
유동파라핀 | 0.5 |
세테아릴 알코올 | 1.0 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
배합 성분 | 함량(중량%) |
실시예 1 또는 2의 히드록시 피라논 유도체 | 2.0 |
글리세린 | 3.0 |
부틸렌글리콜 | 3.0 |
유동파라핀 | 7.0 |
베타글루칸 | 7.0 |
카보머 | 0.1 |
카프릴릭/카프릭 트리글리세라이드 | 3.0 |
스쿠알란 | 5.0 |
세테아릴 글루코사이드 | 1.5 |
소르비탄 스테아레이트 | 0.4 |
폴리솔베이트 60 | 1.2 |
트리에탄올아민 | 0.1 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
배합 성분 | 함량(중량%) |
실시예 1 또는 2의 히드록시 피라논 유도체 | 2.0 |
글리세린 | 8.0 |
부틸렌글리콜 | 4.0 |
유동파라핀 | 45.0 |
베타글루칸 | 7.0 |
카보머 | 0.1 |
카프릴릭/카프릭 트리글리세라이드 | 3.0 |
밀납 | 4.0 |
세테아릴 글루코사이드 | 1.5 |
세스퀴 올레인산 소르비탄 | 0.9 |
바세린 | 3.0 |
파라핀 | 1.5 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
배합 성분 | 함량(중량%) |
실시예 1 또는 2의 히드록시 피라논 유도체 | 0.2 |
글리세린 | 4.0 |
폴리비닐알콜 | 15.0 |
히알루론산 추출물 | 5.0 |
베타글루칸 | 7.0 |
알란토인 | 0.1 |
노닐 페닐에테르 | 0.4 |
폴리솔베이트 60 | 1.2 |
에탄올 방부제 | 6.0 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
Claims (8)
- 제1항에 있어서, 상기 조성물은 중간엽줄기세포(mesenchymal stem cell)가 지방세포로 분화되는 것을 촉진하는 것인 피부 볼륨 또는 탄력 증진용 조성물.
- 제1항에 있어서, 상기 조성물은 유효성분의 농도가 조성물 전체 부피를 기준으로 0.01μM 내지 100μM 인 것인 피부 볼륨 또는 탄력 증진용 조성물.
- 제1항에 있어서, 상기 조성물은 지방조직을 증가시키는 것을 특징으로 하는 피부 볼륨 또는 탄력 증진용 조성물.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 조성물은 약학 또는 화장료 조성물인 것인 피부 볼륨 또는 탄력 증진용 조성물.
- 제6항에 있어서, 상기 조성물은 중간엽줄기세포(mesenchymal stem cell)가 지방세포로 분화되는 것을 촉진하는 것인 지방세포 분화 촉진용 조성물.
- 제6항에 있어서, 상기 조성물은 유효성분의 농도가 조성물 전체 부피를 기준으로 0.01μM 내지 100μM 이상인 것인 지방세포 분화 촉진용 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580003446.2A CN105873584B (zh) | 2014-01-20 | 2015-01-20 | 用于促进脂肪细胞分化的包含羟基吡喃酮衍生物化合物的化妆品组合物 |
JP2016542943A JP2017502955A (ja) | 2014-01-20 | 2015-01-20 | ヒドロキシピラノン誘導体化合物を含有する脂肪細胞分化促進用の化粧料組成物 |
US15/107,955 US10251862B2 (en) | 2014-01-20 | 2015-01-20 | Cosmetic composition containing hydroxy pyranone derivative compound for promoting differentiation of adipocytes |
EP15737765.6A EP3097913B1 (en) | 2014-01-20 | 2015-01-20 | Cosmetic use of a hydroxypyranone derivative compound for promoting differentiation of adipocytes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140006640A KR102175468B1 (ko) | 2014-01-20 | 2014-01-20 | 히드록시 피라논 유도체 화합물을 포함하는 지방세포 분화 촉진용 화장료 조성물 |
KR10-2014-0006640 | 2014-01-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015108394A1 true WO2015108394A1 (ko) | 2015-07-23 |
Family
ID=53543210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/000560 WO2015108394A1 (ko) | 2014-01-20 | 2015-01-20 | 히드록시 피라논 유도체 화합물을 포함하는 지방세포 분화 촉진용 화장료 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10251862B2 (ko) |
EP (1) | EP3097913B1 (ko) |
JP (1) | JP2017502955A (ko) |
KR (1) | KR102175468B1 (ko) |
CN (1) | CN105873584B (ko) |
WO (1) | WO2015108394A1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108473457A (zh) * | 2015-12-01 | 2018-08-31 | 爱茉莉太平洋股份有限公司 | 一种新型的羟基吡喃酮化合物、其制备方法及包含其的化妆品组合物 |
CN108495848A (zh) * | 2015-12-01 | 2018-09-04 | 爱茉莉太平洋股份有限公司 | 一种新型的羟基吡喃酮化合物、其制备方法及包含其的化妆品组合物 |
WO2019066380A1 (ko) * | 2017-09-29 | 2019-04-04 | (주)아모레퍼시픽 | 트리메톡시 페닐 화합물을 포함하는 지방세포 분화 또는 아디포넥틴 촉진용 조성물 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190036971A (ko) * | 2017-09-28 | 2019-04-05 | (주)아모레퍼시픽 | 트리메틸 사이클로헥센 화합물을 포함하는 아디포넥틴 생성 촉진용 조성물 |
CN115721575A (zh) * | 2022-05-10 | 2023-03-03 | 株式会社爱茉莉太平洋 | 缓和皮肤敏感性或者抑制皮脂分泌用组合物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100482668B1 (ko) * | 2002-06-22 | 2005-04-13 | 주식회사 태평양 | 히드록시 피라논 유도체 및 이의 제조방법 |
KR20090130801A (ko) * | 2008-06-16 | 2009-12-24 | (주)아모레퍼시픽 | 인삼씨 추출물을 함유하는 피부 외용제 조성물 |
KR20110106235A (ko) * | 2010-03-22 | 2011-09-28 | 가톨릭대학교 산학협력단 | 사람 하비갑개 유래 중간엽 기질세포로부터 연골, 골, 신경세포 또는 지방세포를 분화시키는 방법 |
KR101078419B1 (ko) * | 2009-03-20 | 2011-10-31 | 주식회사 스템메디언스 | 양수 내 태아 유래 중간엽줄기세포를 이용한 피부 상태개선용 조성물 |
KR101206097B1 (ko) * | 2009-03-20 | 2012-11-28 | (주)아모레퍼시픽 | 인간 중간엽줄기세포의 지방세포로의 분화 촉진용 조성물 |
KR20140006640A (ko) | 2012-07-06 | 2014-01-16 | 주식회사 라온익스 | Sip 서버를 이용한 방문자 확인 방법 및 장치 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6007829A (en) * | 1998-12-17 | 1999-12-28 | Cheesebrough-Pond's Usa Co. | Cosmetic skin care compositions containing succinate compounds |
AU1701501A (en) * | 1999-12-14 | 2001-06-25 | Unilever Plc | Cosmetic skin conditioning compositions containing red yeast rice extract |
JP5060012B2 (ja) * | 2000-07-13 | 2012-10-31 | タカラバイオ株式会社 | 医薬又は化粧料 |
JP5665276B2 (ja) | 2008-02-27 | 2015-02-04 | 花王株式会社 | 皮膚老化予防又は改善剤 |
KR20110001407A (ko) | 2009-06-30 | 2011-01-06 | (주)아모레퍼시픽 | 지황, 감초, 의이인, 맥아, 모과, 오가피, 또는 갈근 추출물을 함유하는 지방 세포 분화 촉진 조성물 |
KR101516582B1 (ko) | 2012-03-23 | 2015-05-11 | 주식회사 엔자임바이오 | 카르니틴 팔미토일트랜스퍼라아제-1의 활성을 촉진시켜 지방세포 내 지방의 분해를 향상시킬 수 있는 청고추 유래 항비만용 조성물 |
-
2014
- 2014-01-20 KR KR1020140006640A patent/KR102175468B1/ko active IP Right Grant
-
2015
- 2015-01-20 US US15/107,955 patent/US10251862B2/en active Active
- 2015-01-20 CN CN201580003446.2A patent/CN105873584B/zh active Active
- 2015-01-20 JP JP2016542943A patent/JP2017502955A/ja active Pending
- 2015-01-20 EP EP15737765.6A patent/EP3097913B1/en active Active
- 2015-01-20 WO PCT/KR2015/000560 patent/WO2015108394A1/ko active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100482668B1 (ko) * | 2002-06-22 | 2005-04-13 | 주식회사 태평양 | 히드록시 피라논 유도체 및 이의 제조방법 |
KR20090130801A (ko) * | 2008-06-16 | 2009-12-24 | (주)아모레퍼시픽 | 인삼씨 추출물을 함유하는 피부 외용제 조성물 |
KR101078419B1 (ko) * | 2009-03-20 | 2011-10-31 | 주식회사 스템메디언스 | 양수 내 태아 유래 중간엽줄기세포를 이용한 피부 상태개선용 조성물 |
KR101206097B1 (ko) * | 2009-03-20 | 2012-11-28 | (주)아모레퍼시픽 | 인간 중간엽줄기세포의 지방세포로의 분화 촉진용 조성물 |
KR20110106235A (ko) * | 2010-03-22 | 2011-09-28 | 가톨릭대학교 산학협력단 | 사람 하비갑개 유래 중간엽 기질세포로부터 연골, 골, 신경세포 또는 지방세포를 분화시키는 방법 |
KR20140006640A (ko) | 2012-07-06 | 2014-01-16 | 주식회사 라온익스 | Sip 서버를 이용한 방문자 확인 방법 및 장치 |
Non-Patent Citations (3)
Title |
---|
EXP. CELL RES., vol. 312, 2006, pages 1856 - 1864 |
J. CELL SCI, vol. 119, 2006, pages 2204 - 2213 |
SCIENCE, vol. 284, 1999, pages 143 - 146 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108473457A (zh) * | 2015-12-01 | 2018-08-31 | 爱茉莉太平洋股份有限公司 | 一种新型的羟基吡喃酮化合物、其制备方法及包含其的化妆品组合物 |
CN108495848A (zh) * | 2015-12-01 | 2018-09-04 | 爱茉莉太平洋股份有限公司 | 一种新型的羟基吡喃酮化合物、其制备方法及包含其的化妆品组合物 |
TWI703137B (zh) * | 2015-12-01 | 2020-09-01 | 南韓商愛茉莉太平洋股份有限公司 | 新穎羥基吡喃酮化合物、其製備方法和含有其的化妝品組成物 |
TWI715687B (zh) * | 2015-12-01 | 2021-01-11 | 南韓商愛茉莉太平洋股份有限公司 | 新穎羥基吡喃酮化合物、其製備方法和含有其的化妝品組成物 |
CN108473457B (zh) * | 2015-12-01 | 2021-08-20 | 爱茉莉太平洋股份有限公司 | 一种新型的羟基吡喃酮化合物、其制备方法及包含其的化妆品组合物 |
WO2019066380A1 (ko) * | 2017-09-29 | 2019-04-04 | (주)아모레퍼시픽 | 트리메톡시 페닐 화합물을 포함하는 지방세포 분화 또는 아디포넥틴 촉진용 조성물 |
KR20190037754A (ko) * | 2017-09-29 | 2019-04-08 | (주)아모레퍼시픽 | 트리메톡시 페닐 화합물을 포함하는 지방세포 분화 또는 아디포넥틴 촉진용 조성물 |
KR102040900B1 (ko) | 2017-09-29 | 2019-11-06 | (주)아모레퍼시픽 | 트리메톡시 페닐 화합물을 포함하는 지방세포 분화 또는 아디포넥틴 촉진용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR20150086681A (ko) | 2015-07-29 |
EP3097913A4 (en) | 2017-06-28 |
KR102175468B1 (ko) | 2020-11-06 |
EP3097913A1 (en) | 2016-11-30 |
CN105873584A (zh) | 2016-08-17 |
US20160324824A1 (en) | 2016-11-10 |
JP2017502955A (ja) | 2017-01-26 |
EP3097913B1 (en) | 2021-03-03 |
US10251862B2 (en) | 2019-04-09 |
CN105873584B (zh) | 2019-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015108394A1 (ko) | 히드록시 피라논 유도체 화합물을 포함하는 지방세포 분화 촉진용 화장료 조성물 | |
WO2021149880A1 (ko) | 오이, 가지 및 달팽이의 혼합 추출물을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
WO2018164369A1 (ko) | 효소 처리된 무궁화 추출물을 유효성분으로 함유하는 피부 주름 개선용 조성물 | |
WO2016056781A1 (ko) | 알파인 웜우드 추출물을 포함하는 탈모 방지 또는 육모 촉진용 조성물 | |
WO2018117725A1 (ko) | 수산동물 발효물을 포함하는 탈모 방지 및 육모 촉진을 위한 조성물 | |
WO2014034802A1 (ja) | トランスグルタミナーゼ活性化剤 | |
WO2020040432A1 (ko) | 인삼열매 추출물을 유효성분으로 함유하는 근육 질환의 예방 또는 치료용 약학적 조성물 | |
WO2021080129A1 (ko) | 하이드란제놀 또는 필로둘신을 유효성분으로 하는 피부장벽 강화 및 아토피 피부염 개선용 조성물 | |
WO2016056780A1 (ko) | 알피나 골무꽃 추출물을 포함하는 탈모 방지 또는 육모 촉진용 조성물 | |
WO2018080039A1 (ko) | 단풍콩잎 추출물을 함유하는 탈모방지 또는 발모개선용 조성물 | |
WO2015167240A1 (ko) | 알피나 골무꽃 추출물을 포함하는 조성물 | |
WO2019139403A1 (ko) | 세리신, 사상자 추출물 및 겨우살이 추출물을 포함하는, 피부 재생, 진정 또는 상처 치유용 조성물 | |
WO2016003120A1 (ko) | 알피나 골무꽃 추출물을 포함하는 미백용 조성물 | |
WO2021080298A1 (ko) | 엔테로코커스 패칼리스를 유효성분으로 함유하는 비만 또는 비만으로부터 유도된 대사증후군의 예방 또는 치료용 조성물 | |
WO2018186724A1 (ko) | 꽃벵이 추출물 또는 이로부터 분리된 화합물을 유효성분으로 함유하는 피부 보습 또는 피부 주름 개선용 조성물 | |
WO2015152653A1 (ko) | 알파인 웜우드 추출물을 포함하는 조성물 | |
WO2019031655A1 (ko) | 티몰을 유효성분으로 함유하는 피부 주름 또는 아토피성 피부염의 예방 또는 치료용 조성물 | |
WO2016117762A1 (ko) | 구스베리 추출물 또는 글루타티온을 포함하는 조성물 | |
WO2019164090A1 (ko) | 앉은 부채 추출물 또는 이의 분획물을 유효성분으로 포함하는 주름 개선용 조성물 | |
WO2021002642A1 (ko) | 뱀독을 포함하는 류마티스 관절염의 예방 또는 치료용 조성물 | |
WO2015152552A1 (ko) | 알파인 웜우드 추출물을 포함하는 조성물 | |
WO2018155933A1 (ko) | 아쿠아포린-3의 발현을 증가시키는 6,7-디메톡시-2,2-디메틸-2h-크로멘 및 이의 용도 | |
WO2020111297A1 (ko) | 타임 복합 추출물을 유효성분으로 함유하는 피부 보습용 화장료 조성물 | |
WO2014185610A1 (ko) | 밀기울 추출물을 유효성분으로 포함하는 탈모 방지 또는 육모 촉진 조성물 | |
WO2015167239A1 (ko) | 산형화 추출물을 포함하는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15737765 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016542943 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15107955 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2015737765 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015737765 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |